Janus Capital Management Raised Regeneron Pharmaceuticals (REGN) Position; Cytori Therapeutics DE (CYTX) Shorts Raised By 51.2%

June 21, 2017 - By Peter Erickson

Janus Capital Management Llc increased Regeneron Pharmaceuticals (REGN) stake by 1.99% reported in 2016Q4 SEC filing. Janus Capital Management Llc acquired 16,185 shares as Regeneron Pharmaceuticals (REGN)’s stock rose 21.24%. The Janus Capital Management Llc holds 831,043 shares with $305.06M value, up from 814,858 last quarter. Regeneron Pharmaceuticals now has $58.27B valuation. The stock increased 5.39% or $26.69 during the last trading session, reaching $522.02. About 1.74 million shares traded or 90.52% up from the average. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since June 21, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Cytori Therapeutics DE (NASDAQ:CYTX) had an increase of 51.2% in short interest. CYTX’s SI was 1.23 million shares in June as released by FINRA. Its up 51.2% from 815,400 shares previously. With 315,700 avg volume, 4 days are for Cytori Therapeutics DE (NASDAQ:CYTX)’s short sellers to cover CYTX’s short positions. The SI to Cytori Therapeutics DE’s float is 5.58%. The stock decreased 1.94% or $0.02 on June 21, reaching $1.01. About 222,322 shares traded. Cytori Therapeutics Inc (NASDAQ:CYTX) has declined 65.60% since June 21, 2016 and is downtrending. It has underperformed by 82.30% the S&P500.

Among 5 analysts covering Cytori Therapeutics (NASDAQ:CYTX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cytori Therapeutics had 6 analyst reports since August 8, 2015 according to SRatingsIntel. The firm has “Buy” rating by TH Capital given on Monday, August 10. Maxim Group maintained Cytori Therapeutics Inc (NASDAQ:CYTX) on Saturday, August 8 with “Buy” rating. The stock of Cytori Therapeutics Inc (NASDAQ:CYTX) has “Hold” rating given on Friday, September 4 by Zacks. The company was maintained on Wednesday, May 31 by Maxim Group.

Cytori Therapeutics, Inc. is a biotechnology firm engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The company has market cap of $32.06 million. The Firm develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It currently has negative earnings. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation.

Janus Capital Management Llc decreased Weyerhaeuser Co (NYSE:WY) stake by 16,073 shares to 387,831 valued at $11.67 million in 2016Q4. It also reduced Norfolk Southern Corp (NYSE:NSC) stake by 6,360 shares and now owns 30,354 shares. Motorola Solutions Inc (NYSE:MSI) was reduced too.

Among 22 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 12 have Buy rating, 0 Sell and 10 Hold. Therefore 55% are positive. Regeneron Pharmaceuticals Inc. had 49 analyst reports since July 28, 2015 according to SRatingsIntel. Wells Fargo downgraded the shares of REGN in report on Wednesday, April 20 to “Market Perform” rating. Argus Research maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Thursday, August 6 with “Buy” rating. The firm has “Outperform” rating given on Tuesday, September 1 by Raymond James. Chardan Capital Markets downgraded it to “Sell” rating and $400 target in Monday, January 25 report. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned “Buy” rating by RBC Capital Markets on Monday, August 31. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Equal-Weight” rating given on Friday, October 2 by Morgan Stanley. The firm has “Neutral” rating given on Friday, August 5 by Robert W. Baird. The firm has “Outperform” rating by RBC Capital Markets given on Monday, July 27. Brean Capital reinitiated it with “Buy” rating and $489 target in Tuesday, March 8 report. The stock has “Outperform” rating by Wells Fargo on Friday, December 4.

Investors sentiment increased to 1.25 in Q4 2016. Its up 0.29, from 0.96 in 2016Q3. It improved, as 48 investors sold REGN shares while 151 reduced holdings. 60 funds opened positions while 188 raised stakes. 70.27 million shares or 1.15% less from 71.09 million shares in 2016Q3 were reported. 6,571 are owned by Gateway Advisers Ltd Liability Corporation. Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 0.07% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Alps, Colorado-based fund reported 1,086 shares. Sumitomo Mitsui Asset Management Com Ltd, a Japan-based fund reported 5,827 shares. 2,093 were accumulated by Tiverton Asset Mngmt Ltd Limited Liability Company. Lagoda Inv Ltd Partnership has 9.2% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Rafferty Asset Mngmt reported 2,658 shares or 0.04% of all its holdings. Alphamark Advisors Limited Liability Corporation stated it has 33 shares or 0.01% of all its holdings. 1,459 are owned by Rampart Inv Mgmt Co Lc. Ithaka Group Lc holds 3.31% or 45,733 shares in its portfolio. Finemark Natl Bank Tru accumulated 220 shares or 0.01% of the stock. Keybank National Association Oh holds 0.01% or 2,255 shares. Kbc Group Inc Nv has 0.03% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 7,357 shares. World Investors accumulated 7.76M shares or 0.72% of the stock. D E Shaw And Communications, New York-based fund reported 8,799 shares.

Since January 11, 2017, it had 2 insider buys, and 8 sales for $74.63 million activity. $9.90M worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares were sold by Terifay Robert J. Another trade for 136,050 shares valued at $65.06M was made by Sanofi on Friday, June 2. GOLDSTEIN JOSEPH L sold $482,550 worth of stock. BROWN MICHAEL S also sold $1.35 million worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares. On Wednesday, June 14 STAHL NEIL sold $4.01 million worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) or 8,567 shares. On Thursday, May 25 the insider VAGELOS P ROY sold $4.26M.